Plaque Psoriasis Clinical Trials

34 recruiting

Plaque Psoriasis Trials at a Glance

37 actively recruiting trials for plaque psoriasis are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 3 with 11 trials, with the heaviest enrollment activity in Toronto, Hangzhou, and Beijing. Lead sponsors running plaque psoriasis studies include Bristol-Myers Squibb, Oruka Therapeutics, Inc., and UCB Biopharma SRL.

Browse plaque psoriasis trials by phase

Treatments under study

About Plaque Psoriasis Clinical Trials

Looking for clinical trials for Plaque Psoriasis? There are currently 34 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plaque Psoriasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plaque Psoriasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 1

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled12 locationsNCT06888193
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
Bristol-Myers Squibb366 enrolled120 locationsNCT06979453
Recruiting
Not Applicable

Modifying PEST for Psoriatic Arthritis Screening

Psoriatic ArthritisPlaque Psoriasis
Novartis Pharmaceuticals502 enrolled21 locationsNCT06382051
Recruiting
Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
InventisBio Co., Ltd477 enrolled1 locationNCT07326813
Recruiting
Phase 3

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Psoriatic ArthritisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL90 enrolled16 locationsNCT06506916
Recruiting
Phase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled27 locationsNCT07474792
Recruiting
Phase 2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.80 enrolled17 locationsNCT07449702
Recruiting
Phase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled351 locationsNCT07116967
Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
AbbVie700 enrolled70 locationsNCT07039110
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL168 enrolled50 locationsNCT06425549
Recruiting
Phase 3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

Plaque Psoriasis
Takeda110 enrolled40 locationsNCT07250802
Recruiting
Phase 2

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis
Oruka Therapeutics, Inc.160 enrolled26 locationsNCT07290569
Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Atopic DermatitisHidradenitis SuppurativaAcne+3 more
Innovaderm Research Inc.500 enrolled1 locationNCT05994976
Recruiting

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Hidradenitis SuppurativaJuvenile Idiopathic ArthritisPediatric Plaque Psoriasis
Novartis Pharmaceuticals76 enrolled1 locationNCT07243782
Recruiting
Early Phase 1

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Plaque PsoriasisVitamin D3
Wright State University24 enrolled1 locationNCT04036188
Recruiting
Phase 3

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.383 enrolled46 locationsNCT06842199
Recruiting
Phase 3

A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

Plaque Psoriasis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.537 enrolled55 locationsNCT07357831
Recruiting

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Plaque Psoriasis
Bristol-Myers Squibb150 enrolled5 locationsNCT06512337
Recruiting
Phase 2

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
Beijing InnoCare Pharma Tech Co., Ltd.172 enrolled1 locationNCT07251998
Recruiting
Phase 3

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
InventisBio Co., Ltd390 enrolled1 locationNCT07130604